Picard Medical, Inc.
No SEC Form 4 filings for $PMI in the last 30 days.
See all $PMI insider activity →Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
Picard Medical, Inc. (PMI) shares rose 40% after reporting Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales of SynCardia products. Gross profit improved to $0.6M, and net loss narrowed by 16%. The company also advanced its Emperor Total Artificial Heart platform and completed a reverse stock split to comply with NYSE listing requirements.
Over the past 7 days, alphai's AI scored 4 news stories mentioning PMI (Picard Medical, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent PMI coverage spans earnings, market movers and sector analysis.
Moderate pre‑market gain indicates bullish sentiment.
Positive earnings beat with strong revenue growth.
Strong quarterly results and reverse split news drove a sharp price surge.
Revenue beat triggers strong buying pressure, compressing shorts and attracting speculative interest.
Improved revenue and reduced loss may support short-term price appreciation, but small market cap limits upside.
alphai scores every news story that mentions PMI with an AI model for sentiment and relevance, and aggregates insider trades from Picard Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readPicard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
3 min readPicard Medical, Inc. (PMI) shares rose 40% after reporting Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales of SynCardia products. Gross profit improved to $0.6M, and net loss narrowed by 16%. The company also advanced its Emperor Total Artificial Heart platform and completed a reverse stock split to comply with NYSE listing requirements.
2 min readPicard Medical Inc. stock surged 43.9% in pre-market trading after reporting Q2 2026 revenue of $2.95M, exceeding expectations of $1.55M. The company also issued an investor presentation. The S&P 500, Nasdaq, and Dow were down slightly, indicating the rally was company-specific.
1 min readPicard Medical reported Q2 2026 revenue growth of 39% to $3.0M, with a 16% reduction in net loss to $5.7M. Year-to-date revenue rose 50% to $4.1M, with $0.9M in gross profit. The company is advancing its Emperor Total Artificial Heart platform and focusing on operational improvements. PMI completed a 1-for-50 reverse stock split to comply with NYSE American listing standards.
2 min readPicard Medical reported a 50% revenue increase to $4.1M, driven by U.S. sales, but a wider net loss of $13.3M due to R&D and SG&A expenses. The company faces going concern risks, customer concentration, and litigation, while investing in next-gen heart tech.
1 min readNicotine pouches are gaining investor attention as cigarette sales decline, with brands like PMI's Zyn and BAT's Velo showing rapid growth and strong margins. BAT expects the global pouch market to grow from £4B in 2025 to £11B by 2030, with pouch volumes in Asia, Middle East, and Africa up 27.5% in H1 2026. PMI reported higher profitability for pouches compared to cigarettes and heated tobacco. Analysts note that pouch performance influences tobacco-company valuations, but wider adoption faces
5 min readPhilip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.
6 min readPerseverance Metals Inc. (TSXV: PMI) says its summer 2026 drill program has started at the Lac Gayot Ni-Cu-Co-PGE project in Québec, focusing on the Venus East Trend. The company plans at least 5,000 metres of drilling plus follow-up of EM anomalies and new surface zones. It also reports Voyageur drilling is delayed but rig testing should begin this week, and granted 75,000 options at $0.65.
4 min readPicard Medical, Inc. (PMI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pmi20260720_8k.htm false 0002030617 0002030617 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event repor
2 min read
